Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
Status:
Recruiting
Trial end date:
2036-02-01
Target enrollment:
Participant gender:
Summary
This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety
and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or
refractory CD30+ classical Hodgkin Lymphoma.